AstraZeneca and MRC form Landmark Collaboration - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

AstraZeneca and MRC form Landmark Collaboration


ePT--the Electronic Newsletter of Pharmaceutical Technology

In an initiative that could signal a new era in private–public partnerships, AstraZeneca will make 22 compounds available for free to medical researchers next year for projects funded by the United Kingdom’s (UK) Medical Research Council (MRC). The collaboration is yet another boost to UK research and acknowledges the long, complex, and expensive process of drug development by giving UK researchers access to compounds and funds that will allow studies to explore new treatment opportunities through better understanding of disease mechanisms. The MRC, which has fostered 29 Nobel Prize winners, has supported high-quality science for 100 years and is active several disease areas.

“Innovative collaborations are playing a crucial role in finding ways to unlock the potential of new treatments,” said David Brennan, AstraZeneca’s CEO, in a press release, “The UK has a strong heritage of research excellence in life sciences. We hope that in sharing these valuable clinical compounds with academic scientists through the MRC, new discoveries will be made by exploring additional uses of these compounds.”

As part of the collaboration, MRC is requesting research proposals from across the UK. A total of £10 million ($15.6 million) will be awarded to the projects judged to best use the AstraZeneca-developed compounds. Notably, these projects must not directly contribute to AstraZeneca’s active programs to secure the funding.

“The MRC is delighted to be partnering [with] AstraZeneca in this exciting new approach towards understanding disease mechanisms in humans and thereby speeding the development of new treatments,” said Sir John Savill, MRC’s chief executive, in the press release. “The initiative marks a new era in medical discovery, open innovation and public-private collaboration.”

Though IP generated will vary from project to project, AstraZeneca will retain rights over the chemical composition of the compounds, and academic institutions will own any new research findings. New research produced by the collaboration will be made available to the broader scientific community.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here